Swiss pharma giant Roche to buy US-listed 89bio for $2.4 bln in cash
PositiveFinancial Markets

Swiss pharmaceutical giant Roche has announced its acquisition of US-listed 89bio for $2.4 billion in cash. This strategic move highlights Roche's commitment to expanding its portfolio in the biopharmaceutical sector, particularly in innovative treatments. The acquisition is expected to enhance Roche's capabilities in addressing unmet medical needs, which is crucial for maintaining its competitive edge in the industry.
— Curated by the World Pulse Now AI Editorial System